2017
DOI: 10.1002/ardp.201700135
|View full text |Cite
|
Sign up to set email alerts
|

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

Abstract: A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED values of 25.10 and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(7 citation statements)
references
References 39 publications
0
7
0
Order By: Relevance
“…Abd-Allah and collaborators recently studied the anticonvulsant activity of a series of coumarin derivatives, achieved by merging two or more pharmacophoric scaffolds in order to create new chemical entities with an improved biological activity [180]. The compounds here described possess all the necessary elements to exert anti-convulsant activity: a lipophilic aryl ring, a hydrogen-bonding domain and an electron-donor moiety [178,179,181,182]. All the compounds were initially screened (phase I) using two standard animal seizure models, subcutaneous pentylenetetrazole (scPTZ) and maximal electric shock (MES) seizure tests using ethosuximide as reference drug.…”
Section: Anticonvulsant Activitymentioning
confidence: 99%
“…Abd-Allah and collaborators recently studied the anticonvulsant activity of a series of coumarin derivatives, achieved by merging two or more pharmacophoric scaffolds in order to create new chemical entities with an improved biological activity [180]. The compounds here described possess all the necessary elements to exert anti-convulsant activity: a lipophilic aryl ring, a hydrogen-bonding domain and an electron-donor moiety [178,179,181,182]. All the compounds were initially screened (phase I) using two standard animal seizure models, subcutaneous pentylenetetrazole (scPTZ) and maximal electric shock (MES) seizure tests using ethosuximide as reference drug.…”
Section: Anticonvulsant Activitymentioning
confidence: 99%
“…Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor (Partap at al., 2017). Simultaneous blockade of more than one pathway is considered to be a promising approach to overcome the low efficacy and acquired resistance of cancer therapies.…”
Section: Biological Activitiesmentioning
confidence: 78%
“…Compound 475 emerged as an effective and safe anticonvulsant in both MES and scPTZ models. The compound also exhibited notable increase in GABA level (1.7-fold) compared to control which was attributed to its good binding property with the GABA A receptor ( Partap et al, 2017 ). Recently, Sahoo et al ( Sahoo et al, 2019 ) synthesized several benzimidazole derivatives and disclosed that compounds 476–480 exhibited notable anticonvulsant potency (around 70–80%) in comparison to standard drug phenytoin.…”
Section: Biological Activitiesmentioning
confidence: 99%